Denali Therapeutics Inc. (DNLI) Debt-to-equity % [USD] 2018 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Denali Therapeutics Inc. quarterly Debt-to-equity history and growth rate from 2018 to 2024.
Denali Therapeutics Inc. Debt-to-equity for the quarter ending March 31, 2024 was 10.1 %, a 77.7% decline year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	10.1	-35.3	-77.7%	Mar 31, 2024
Q4 2023	18.7	-26.3	-58.5%	Dec 31, 2023
Q3 2023	25.5	-21.2	-45.5%	Sep 30, 2023
Q2 2023	34.8	-9.93	-22.2%	Jun 30, 2023
Q1 2023	45.5	+2.11	+4.87%	Mar 31, 2023
Q4 2022	45	+2.63	+6.21%	Dec 31, 2022
Q3 2022	46.7	+5.88	+14.4%	Sep 30, 2022
Q2 2022	44.8	+8.64	+23.9%	Jun 30, 2022
Q1 2022	43.4	+9.6	+28.4%	Mar 31, 2022
Q4 2021	42.4	+11.9	+39.2%	Dec 31, 2021
Q3 2021	40.8	+13.2	+47.8%	Sep 30, 2021
Q2 2021	36.1	+3.21	+9.76%	Jun 30, 2021
Q1 2021	33.8	-0.55	-1.6%	Mar 31, 2021
Q4 2020	30.4	-4.95	-14%	Dec 31, 2020
Q3 2020	27.6	-2.86	-9.39%	Sep 30, 2020
Q2 2020	32.9	+6.86	+26.3%	Jun 30, 2020
Q1 2020	34.3	+12.5	+57.1%	Mar 31, 2020
Q4 2019	35.4	+17.9	+103%	Dec 31, 2019
Q3 2019	30.5	+17.1	+128%	Sep 30, 2019
Q2 2019	26			Jun 30, 2019
Q1 2019	21.9			Mar 31, 2019
Q4 2018	17.4			Dec 31, 2018
Q3 2018	13.3			Sep 30, 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.